SHL Telemedicine PE Ratio 2022-2024 | SHLT
Current and historical p/e ratio for SHL Telemedicine (SHLT) from 2022 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. SHL Telemedicine PE ratio as of January 07, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| SHL Telemedicine PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-07 | 2.86 | inf | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.041B | $0.057B |
| SHL Telemedicine Ltd is engaged in developing and marketing personal telemedicine solutions, with a focus on cardiovascular and related diseases. Its solutions for healthcare professionals include: CHF monitoring service which supports patients suffering from Congestive Heart Failure; COPD monitoring service that supports patients suffering from Chronic Obstructive Pulmonary Disease and Readmission Solutions for reducing heart-related readmissions. SHL Telemedicine Ltd is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inspire Medical Systems (INSP) | United States | $5.669B | 176.81 |
| Hims & Hers Health (HIMS) | United States | $5.506B | 140.00 |
| Tempus AI (TEM) | United States | $5.393B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $2.799B | 0.00 |
| Enovis (ENOV) | United States | $2.475B | 16.78 |
| Privia Health (PRVA) | United States | $2.357B | 196.40 |
| Azenta (AZTA) | United States | $2.286B | 122.05 |
| Omnicell (OMCL) | United States | $2.053B | 67.15 |
| 10x Genomics (TXG) | United States | $1.718B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.568B | 0.00 |
| Schrodinger (SDGR) | United States | $1.486B | 0.00 |
| Phreesia (PHR) | United States | $1.464B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.846B | 0.00 |
| Standard BioTools (LAB) | United States | $0.651B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.563B | 0.00 |
| Talkspace (TALK) | United States | $0.529B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.476B | 82.40 |
| Health Catalyst (HCAT) | United States | $0.446B | 0.00 |
| TruBridge (TBRG) | United States | $0.297B | 86.52 |
| Pulmonx (LUNG) | United States | $0.257B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.209B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.114B | 0.00 |
| American Well (AMWL) | United States | $0.108B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.090B | 0.00 |
| HeartBeam (BEAT) | United States | $0.063B | 0.00 |
| CareCloud (CCLD) | United States | $0.062B | 0.00 |
| Outset Medical (OM) | United States | $0.061B | 0.00 |
| 111 (YI) | China | $0.054B | 0.00 |
| Zepp Health (ZEPP) | China | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.043B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.018B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.016B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.016B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.012B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.008B | 0.00 |
| Precipio (PRPO) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |